Table 2.

Univariate and multivariate Cox regression analyses of clinical characteristics associated with 5-years OS.

Clinical characteristics	Univariate analysis			Multivariate analysis
	HR	95% CI	p value	HR	95% CI	p value
Age (≤50 vs. >50)	1.390	0.971–1.988	0.072	1.391	0.898–2.157	0.140
Race (Asian vs. non-Asian)	1.304	0.482–3.525	0.601
Subdivision (left/right vs. bilateral)	0.949	0.685–1.314	0.751
Stage (I + II vs. III + IV)	1.459	0.918–2.321	0.11	0.887	0.573–1.375	0.593
Grade (G1 + G2 vs. G3)	1.263	0.930–1.715	0.135
Lymphatic invasion (Y vs. N)	1.463	0.845–2.533	0.174
Venous invasion (Y vs. N)	0.978	0.510–1.878	0.948
Residual tumor size (>10 mm vs. ≤10 mm)	1.294	1.123–1.490	3.56E-04	1.393	1.141–1.700	1.11E−03
Chemotherapy (Y vs. N)	0.276	0.178–0.427	8.11E-09	—	—	1
Targeted molecular therapy (Y vs. N)	0.573	0.320–1.029	0.062
Hormone therapy (Y vs. N)	0.821	0.511–1.319	0.416
Immunotherapy (Y vs. N)	0.473	0.175–1.273	0.138	0.636	0.229–1.769	0.386
Radiation therapy (Y vs. N)	0.721	0.418–1.242	0.238
Primary therapy outcomes (SD + PD vs. CR + PR)	0.321	0.215–0.479	2.57E−08	0.430	0.268–0.689	4.59E−04
New tumor event after initial treatment (Y vs. N)	1.150	0.843–1.568	0.377
Platinum-free interval (≥6 months vs. <6 months)	2.233	1.907–2.615	2.07E−23	2.110	1.741–2.558	2.85E−14
ICB response prediction (R vs. NR)	0.793	0.589–1.068	0.127	0.743	0.474–1.163	0.194
Infiltration score (low vs. high)	0.820	0.604–1.111	0.201	0.798	0.513–1.241	0.317
CAPG expression (high vs. low)	1.359	1.025–1.801	0.033	1.713	1.196–2.454	3.32E−03

Abbreviations: HR: hazard ratio; CI: confidence interval; Y: yes; N: no; SD: stable disease; PD: progressive disease; CR: complete response; PR: partial response; R: response; NR: not response. Italic values indicate p < 0.05.